A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Key claim: This early-phase trial evaluates selinexor monotherapy for efficacy (spleen volume reduction) and safety in JAK inhibitor-naïve myelofibrosis patients with normal to moderately reduced platelet counts.
Abstract
The main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.
Why this matters
Most XPO1-inhibitor development in MF has paired selinexor with ruxolitinib (SENTRY) or pacritinib, leaving the single-agent activity of selinexor in JAKi-naïve disease undefined. This trial isolates selinexor’s contribution and explicitly enrolls patients with moderate thrombocytopenia — a group often excluded from full-dose ruxolitinib — potentially carving out a new monotherapy niche if spleen response and tolerability are confirmed.